News

You are here

Novosanis develops UrNCollect TM for SelectMDx for Prostate Cancer IVD kit of MDxHealth
Colli-Pee
Colli-Pee US FDA registered
Novosanis, a medical device company based in Wijnegem Belgium, together with GeneFirst, a molecular diagnostic company based in Oxfordshire UK, announced CE Marking and launch of...
Prostate cancer is the most common male cancer, with around 400,000 new cases every year in Europe.

Pages